MLYS 8-K: Press Release Furnished for Q2 2025 Financial Results

Rhea-AI Filing Summary

Mineralys Therapeutics, Inc. furnished a press release announcing its financial results for the quarter ended June 30, 2025 and provided a corporate update; the press release is attached to this Form 8-K as Exhibit 99.1. The Form 8-K states the exhibit is furnished and therefore not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference in other filings except as expressly noted.

The filing confirms the company’s common stock trades under MLYS on Nasdaq and indicates the registrant qualifies as an emerging growth company. No financial tables or numerical results are included in the 8-K text itself; readers must consult Exhibit 99.1 for the full financial details and corporate update.

Insights

Financial Analyst

TL;DR Routine earnings disclosure furnished via Form 8-K; the filing itself contains no financial detail, limiting immediate informational value.

The filing notifies investors that Mineralys furnished a press release with quarterly results for the period ended June 30, 2025, and that the press release is attached as Exhibit 99.1 and is "furnished, not filed." From an analyst perspective, this 8-K is procedural: it signals where to find the operative financial information but does not provide metrics or commentary within the filing text. Investors should review Exhibit 99.1 for revenue, expense, cash position, guidance, and any material corporate updates.

Corporate Governance Specialist

TL;DR Standard disclosure practice observed; the company followed Form 8-K rules by furnishing the press release as Exhibit 99.1.

The Form 8-K confirms compliance with disclosure protocols by furnishing the press release and explicitly stating that the exhibit is not "filed" under Section 18. The document also indicates emerging growth company status and Nasdaq listing under ticker MLYS. Because the filing contains no substantive financial tables or material transaction details, it carries limited immediate governance implications beyond routine transparency and regulatory compliance.

false000193341400019334142025-08-122025-08-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 12, 2025

MINERALYS THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware			001-41614			84-1966887
(State or other jurisdiction of incorporation)			(Commission File Number)			(I.R.S. Employer Identification No.)
			150 N. Radnor Chester Road, Suite F200 Radnor, Pennsylvania 19087
(Address of principal executive offices) (Zip Code)
			(888) 378-6240
(Registrant’s telephone number, include area code)
			N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, par value $0.0001 per share			MLYS			The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 12, 2025, Mineralys Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2025 and provided a corporate update. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.						Description
99.1						Press Release Issued on August 12, 2025
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 12, 2025			MINERALYS THERAPEUTICS, INC.
			By:			/s/ Adam Levy
			Name:			Adam Levy
			Title:			Chief Financial Officer and Secretary

FAQ

What did Mineralys Therapeutics (MLYS) disclose in this Form 8-K?

The company furnished a press release announcing its financial results for the quarter ended June 30, 2025 and provided a corporate update; the press release is attached as Exhibit 99.1.

Is the press release attached to the 8-K considered "filed"?

No. The filing explicitly states the information, including Exhibit 99.1, is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act.

Where can I find the actual financial results referenced in the 8-K?

The 8-K attaches the financial results in the press release as Exhibit 99.1; the 8-K text itself does not include numerical financial tables.

What is Mineralys Therapeutics' stock ticker and exchange?

Mineralys Therapeutics' common stock trades under the ticker MLYS on The Nasdaq Stock Market LLC.

Does the 8-K indicate Mineralys is an emerging growth company?

Yes. The filing indicates the registrant is an emerging growth company as defined under the securities rules.